Mamatha Gaddam

Assistant Professor

UAMS

Also affiliated: Gundersen Health System (2018–2022); Rush University Medical Center (2025); Allegheny Health Network (2017–2018); Mayo Clinic (2024)

COM | Internal Med Hem-Onc

5 h-index 21 pubs 82 cited

Research Areas

Biomedical Subjects

Links

Research Group UAMS TRI Profile

OverviewAI-generated summary

Mamatha Gaddam's research focuses on the clinical management and understanding of complex hematological and oncological conditions, particularly those related to immunotherapy and cytopenias. Her work has investigated immune effector cell-associated hemophagocytic lymphohistiocytosis (HLH)-like syndrome, a condition that can arise following treatments like chimeric antigen receptor (CAR) T-cell therapy. Gaddam also studies immune checkpoint inhibitor toxicity in older cancer patients and explores therapeutic advances in myelodysplastic syndromes. Her recent publications include reviews on HLH-like syndromes, CAR T-cell engineering, and real-world outcomes of CAR-T and bispecific T-cell engagers in diffuse large B-cell lymphoma. She has co-authored 22 publications, with an h-index of 5 and 72 total citations. Gaddam collaborates extensively with colleagues at the University of Arkansas for Medical Sciences, including Ankur Varma, Alan Baltz, Nishanth Thalambedu, and Bhavesh Mohan Lal.

Metrics

h-index: 5
Publications: 21
Citations: 82

Positions

Assistant Professor publications 2023–2026

University of Arkansas for Medical Sciences COM | Internal Med Hem-Onc Institutional directory

Selected Publications

CLL-888: Efficacy and Safety of CAR-T Therapy in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis (2026)

Clinical Lymphoma Myeloma & Leukemia DOI OpenAlex
POSTER: CLL-888: Efficacy and Safety of CAR-T Therapy in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis (2026)

Clinical Lymphoma Myeloma & Leukemia DOI OpenAlex
In vivo CAR T-cell engineering in B-cell malignancies: A systematic review of emerging clinical and translational evidence. (2026)

Journal of Clinical Oncology DOI OpenAlex
Social vulnerability index as an independent poor prognostic factor in patients with chronic hematological malignancies in Arkansas. (2026)

Journal of Clinical Oncology DOI OpenAlex
Real-World Survival Outcomes of CAR-T and Bispecific T-cell Engagers in Patients with relapsed/refractory DLBCL (2026)

Transplantation and Cellular Therapy DOI OpenAlex
Impact of the CAR-T era on survival in diffuse large B-cell lymphoma: A u.S. population-based cohort study (2025)

Blood DOI OpenAlex
Can the development of drug-induced rash after mogamulizumab administration predict survival in mycosis fungoides/sezary syndrome? a trinetx-based analysis (2025)

Blood DOI OpenAlex
Navigating Hyperhemolysis in Sickle Cell Disease: Insights from Literature (2025)

Diagnostics 8 citations DOI OpenAlex
Epidemiological and clinical trends in common hematological malignancies in Arkansas: Arkansas Central Cancer Registry (ACCR)-based study. (2025)

Journal of Clinical Oncology DOI OpenAlex
Unveiling Myelodysplastic Syndromes: Exploring Pathogenic Mechanisms and Therapeutic Advances (2025)

Cancers 5 citations DOI OpenAlex
Strategies to Optimize Overutilization of Provider-Ordered Peripheral Blood Smear Review in an University Hospital Setting (2024)

Blood DOI OpenAlex
Impact of Response to Bridging Therapy on Outcomes of CAR-T Therapy in Relapsed/Refractory DLBCL: A Single Center Retrospective Analysis (2024)

Blood DOI OpenAlex
Impact of Social Vulnerability Index and Travel Distance on Access to Chimeric Antigen Receptor T-Cell Therapy (2024)

Blood DOI OpenAlex
Cutaneous Involvement By Peripheral T-Cell Lymphoma: Incidence, Characteristics, Treatment Trends, and Outcomes in the United States (2000-2021) (2024)

Blood DOI OpenAlex
Interdigitating Dendritic Cell Sarcoma and Indeterminate Dendritic Cell Tumor: Patient Characteristics, Prognostic Factors, and Survival Outcomes for Rare Dendritic Cell Neoplasms (2023)

Blood DOI OpenAlex